Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Structural variants in multiple myeloma: impact on outcomes & potential drug targets

Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York, NY, discusses the occurrence of structural variants in multiple myeloma, commenting on the impact of chromoplexy and chromothripsis on patient outcomes, and highlighting the possibility of finding new drivers that can be used as targets for therapy. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.